Guardant Health (NASDAQ:GH) Director Sells $1,231,547.94 in Stock

Guardant Health, Inc. (NASDAQ:GH) Director Steve Krognes sold 9,294 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $132.51, for a total value of $1,231,547.94. Following the sale, the director owned 10,222 shares in the company, valued at approximately $1,354,517.22. This represents a 47.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Guardant Health Price Performance

Shares of Guardant Health stock opened at $125.61 on Monday. Guardant Health, Inc. has a 12-month low of $40.35 and a 12-month high of $134.28. The stock has a market cap of $16.66 billion, a P/E ratio of -37.05 and a beta of 1.61. The business’s 50 day moving average is $99.39 and its 200-day moving average is $101.12.

Institutional Investors Weigh In On Guardant Health

A number of large investors have recently added to or reduced their stakes in the business. Allworth Financial LP raised its stake in Guardant Health by 19.5% in the 3rd quarter. Allworth Financial LP now owns 844 shares of the company’s stock valued at $53,000 after acquiring an additional 138 shares during the period. Eastern Bank increased its position in Guardant Health by 6.9% during the 4th quarter. Eastern Bank now owns 2,160 shares of the company’s stock worth $221,000 after buying an additional 139 shares during the period. First Pacific Financial increased its position in Guardant Health by 33.1% during the 1st quarter. First Pacific Financial now owns 559 shares of the company’s stock worth $52,000 after buying an additional 139 shares during the period. Xponance LLC increased its position in Guardant Health by 2.1% during the 4th quarter. Xponance LLC now owns 9,630 shares of the company’s stock worth $984,000 after buying an additional 199 shares during the period. Finally, Danske Bank A S increased its position in shares of Guardant Health by 20.0% in the fourth quarter. Danske Bank A S now owns 1,200 shares of the company’s stock worth $123,000 after purchasing an additional 200 shares during the period. Institutional investors own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on GH. Wolfe Research began coverage on Guardant Health in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price objective on the stock. Raymond James Financial restated an “outperform” rating and issued a $129.00 price target on shares of Guardant Health in a research note on Monday, February 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Guardant Health in a research note on Tuesday, April 21st. Stifel Nicolaus increased their price target on Guardant Health from $120.00 to $130.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Finally, Piper Sandler set a $127.00 price target on Guardant Health in a research note on Thursday, May 21st. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Guardant Health has an average rating of “Buy” and an average target price of $137.80.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.